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Objectives: REM sleep behavior disorder (RBD) is associated with cognitive dysfunc-
tions and is a risk factor for development of mild cognitive impairment and dementia. 
However, it is unknown whether RBD is associated with faster cognitive decline in already 
established dementia. The main goal of this study was to determine if patients with mild 
dementia with and without RBD differ in progression rate and in specific neuropsycho-
logical measures over 4-year follow-up.
Methods: This longitudinal, prospective study based on data from the DemVest 
study compares neuropsychological measures in a mild dementia cohort. A diag-
nosis of probable RBD (pRBD) was made based on the Mayo Sleep Questionnaire. 
Neuropsychological domains were assessed by Mini Mental State Examination, total 
score and figure copying, California Verbal Learning Test-II, Visual Object and Space 
Perception Cube and Silhouettes, Boston Naming Test, Stroop test, Verbal Category 
Fluency, Trail Making Test A and B.
results: Among the 246 subjects, 47 (19.1%) had pRBD at the baseline, and pRBD 
group was younger and with male predominance. During 4-year follow-up, we did not 
observe any significant differences in the rate of decline in neuropsychological measures. 
Patients with pRBD performed generally poorer in visuoconstructional, visuoperceptual, 
and executive/attention tests in comparison to RBD negative.
conclusion: We did not find any significant differences in progression rate of neurocog-
nitive outcomes between dementia patients with and without RBD.
Keywords: reM sleep behavior disorder, sleep disorders, dementia, cognitive decline, longitudinal study, aD, 
dementia with lewy bodies
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inTrODUcTiOn
REM sleep behavior disorder (RBD) is a parasomnia, char-
acterized by loss of normal muscle atonia in the REM sleep 
phase, accompanied by dream enactment. RBD was initially 
considered as an idiopathic disorder (iRBD); however, 
researches indicate that iRBD is a prodromal symptom of 
neurodegenerative disorders like Parkinson’s disease (PD), 
dementia in Parkinson’s disease (PDD), dementia with Lewy 
bodies (DLB), or multiple system atrophy (MSA), emerging 
after a period of 5–19 years. An observational study published 
by Schenck et al. showed that up to 81% of subjects with iRBD 
developed parkinsonian disorders or dementia after 16 years 
follow-up (1). Another study of Iranzo et al., from 2014, showed 
that estimated risk to develop neurodegenerative diseases was 
90.9% after 14 years (2).
Several studies have shown that there are differences in 
cognitive performance in comparison with non-RBD controls. 
Most predominant are impairments in executive functions and 
attention (3–5), verbal episodic memory (4, 6), decision-making 
(7, 8), and visuospatial abilities (6, 9–11). Nevertheless, poorer 
visuospatial/visuoperceptual ability is debated, not all studies 
confirm this assumption (4, 6, 12, 13). Because there are clear 
similarities with cognitive profile in iRBD and those seen in 
alpha-synucleinopathies, it is proposed that this parasomnia can 
represent an early stadium of alpha-synucleinopathy-dependent 
neurodegeneration.
Idiopathic RBD is a known risk factor for developing mild 
cognitive impairment (MCI). In a population-based study, MCI 
developed in 32% of cognitively intact subjects with iRBD after 
a median of 3.8 year of follow-up with a 2.2-fold increased risk 
of developing MCI (14). In samples from sleep disorder centers, 
the risk is even higher, up to 50–65% compared to 8% in healthy 
subjects (13, 15, 16).
rBD in Parkinson’s Disease
There have also been conducted some studies in Parkinson’s 
disease on patients with and without RBD. For RBD-positive 
PD patients, the frequency of MCI was estimated up to 73% 
(13). Concomitant RBD was found to be associated with poorer 
performance on tests measuring verbal memory, executive, and 
visuospatial functions, compared to patients without RBD (17). 
Data about frequency of developing PDD in RBD positive and 
negative patients are inconsistent. Postuma et al. demonstrated, 
in a 4-year follow-up observation, a clear higher risk of develop-
ing dementia in PD patients with concomitant RBD (18). There 
have also been published results reporting higher occurrence of 
dementia in RBD positive than RBD negative (42 vs. 7%) (19). 
Others, however, have suggested no differences among them 
(20, 21), and two longitudinal studies with 2- and 8-year follow-
up period have not shown any worsening of general cognition 
based on Mini Mental State Examination (MMSE) (22, 23).
To the best of our knowledge, no study to date has systemati-
cally followed a cohort of RBD patients with mild dementia to 
determine cognitive deterioration over time, thus little is known 
about longitudinal changes in neuropsychological profiles in 
MCI and dementia with concomitant RBD.
There are only few studies assessing differences in progres-
sion of cognitive decline globally and in different cognitive 
domains over time but they are only focused on healthy RBD 
subjects or RBD subjects suffering from PD (24). In all previous 
studies, it was underlined the need to collect more data, larger 
samples sizes, and the need for longitudinal observations. With 
our study, we wish to fill this space and characterize dementia 
patients with coexistent RBD.
The purpose of this study was to assess longitudinally cogni-
tive functions in a group of patients with mild dementia with 
and without probable RBD (pRBD). We wanted to answer the 
questions: do MCI and mild dementia patients with and without 
pRBD progress differently in cognition, measured by MMSE, and 
in specific cognitive domains over time? Our hypothesis is that 
presence of RBD can accelerate global dementia progression and 
more rapid deterioration in visuospatial, executive, and attention 
domains.
MaTerials anD MeThODs
sample and Procedures
From a total 261 participants registered in the DemVest study 
database (included between 2005 and 2013), 246 were included 
in our analysis. We excluded five with uncertain diagnoses, and 
those with alcoholic MCI/dementia. Participants were diagnosed 
with dementia according to DSM-IV. Patients were classified 
as having AD when fulfilling the criteria of National Institute 
and Neurological and Communicative Disorders and Stroke-
Alzheimer’s disease and related Disorders (NINDS-ADRDA) 
(25). Diagnosis of DLB was made in accordance with the Third 
Report of the DLB Consortium: “Diagnosis and management of 
dementia with Lewy bodies” (26). PD was diagnosed according 
to the criteria of the United Kingdom Parkinson’s disease Society 
Brain Bank (27) and for PDD Emre’s criteria (28). Patients were 
followed annually, and after 2 and 5 years, a consensus panel of 
dementia experts re-evaluated the clinical diagnoses, based on all 
available information including neuropathologically verification 
for subset of 56 individuals (data not published yet).
ethical issues
This study was carried out and approved in accordance with the 
recommendations of Norwegian Regional Ethics Committee 
and Norwegian authorities for collection of medical data. All 
subjects gave written informed consent in accordance with the 
Declaration of Helsinki.
sleep assessment
Probable RBD diagnosis was assessed with the Mayo Sleep 
Questionnaire (MSQ) (29). The MSQ is a 16-item questionnaire 
specifically designed to detect sleep disturbances, using bed-
partners as informants. Patients received a pRBD diagnosis when 
the core question: “Have you ever seen the patients appear to act 
out his/her dreams while sleeping (punched or flailed arms in the 
air, shouted, screamed)?” (Q1) was answered affirmatively. RBD 
might not be reported continuously even though persisting (22). 
“We, therefore, allocated all patients that reported RBD based on 
TaBle 1 | Demographics and clinical characteristics of REM sleep behavior 
disorder (RBD) positive and negative groups at baseline.
rBD (n = 47) non-rBD 
(n = 174)
p-Value (95% ci) 
or Or*
Age (years), SD 73.4 (7.5) 76.1 (7.6) 0.025  
(0.023, 0.029)
Gender (M), % 30 (63.8) 66 (37.9) 0.001  
(0.177, 0.676)*
Education (years) 9.8 (2.7) 9.7 (3.0) 0.443
MMSE, SD 23.8 (3.1) 23.6 (2.7) 0.515
Positive DATScan (n = 53), 
n (%)
17/23 (73.1) 22/30 (73.9) 0.607*
Dementia with Lewy bodies 
and dementia in Parkinson’s 
disease diagnosis, n (%)
37 (78.7) 52 (29.9) <0.001  
(3.443, 15.361)*
UPDRS III (SD) 12.7 (13.6) 7.0 (11.3) 0.004  
(0.004, 0.006)
Parkinson’s medication, % 28.3 4.7 <0.001  
(3.045, 20.645)*
Dementia medication, % 45.7 43.3 0.773*
Mean duration of RBD at 
baseline (years, SD)
6.91 (8.3) – –
CIRS total (SD) 6.52 (2.7) 5.63 (2.4) 0.051
*Chi-square.
MMSE, Mini Mental State Examination; UPDRS, Unified Parkinson’s Disease Rating 
Scale; CIRS, Chronic Illness Rate Scale.
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the core RBD questions of the MSQ at baseline or follow-up in 
the pRBD group. In longitudinal analysis where patients were 
RBD positive at just one or two follow-ups, they were allocated in 
pRBD at that exact point.”
neuropsychological Tests
Patients were assessed with a comprehensive neuropsychological 
test battery: MMSE, California Verbal Learning Test II, Boston 
Naming Test, Verbal Category Fluency, Stroop tests, Visual 
Object and Space Perception (VOSP) Silhouettes and Cube, Trail 
making Test A and B (TMTB). Details of selection and testing are 
described previously (21).
Other
All patients were assessed with a structured interview, a general 
medical examination, blood samples, and in some cases cerebro-
spinal fluid samples. Parkinsonian symptoms were rated by the 
motor part of Unified Parkinson’s Disease Rating Scale (UPDRS) 
(30). MRI or CT was performed in order to exclude other 
conditions that could influence cognition. 123I-FP-CIT-SPECT 
(DATScan) was performed in some patients with suspected 
DLB. Medication analysis was performed to assess the possibility 
of drug-induced RBD. Diagnosis was neuropathological verified 
in 46 cases.
statistical analysis
Statistical analyses were performed using SPSS IBM Software, v. 
22.0. Clinical and demographic data at baseline were inspected 
with regard to distribution. If data conformed to the normal 
distribution, t-tests were used to assess between-group differ-
ences. For non-normally distributed data the non-parametric 
Mann–Whitney U-test was performed, and Chi-square test for 
categorical data.
Longitudinal analyses were performed using generalized 
linear mixed models (GLMM). In order to examine if pRBD was 
a predictor for more rapid dementia progression or a predictor 
for differential progression in neuropsychological domains, we 
set up a model with time (fu; entered as a categorical variable), 
pRBD (rbd) and the interaction term of fu*rbd as fixed effects. As 
confounders in the analyses, we entered age, education, and sex as 
covariates (fixed effects). Only subjects were set as random effect 
in order to correct for dependency of these clustered measures. 
The analyses were performed using the gamma distribution with 
a log link function for continuous variables and logit link func-
tion for binomial (dichotomous) variables. Variables from Stroop 
W, Stroop C, Stroop CW, and TMT A and TMT B were normally 
distributed and analyses for normal distribution were performed. 
We used Akaike Information Criterion to assess model optimiza-
tion. All cognitive data were entered as raw scores.
resUlTs
Of the total of 246 subjects at the baseline, 122 (49.6%) partici-
pants were diagnosed with probable or possible AD, 10 (4.1%) 
with mixed AD and VaD, 83 (33.7%) with probable or pos-
sible DLB, 18 (7.3%) with PDD, 5 (2%) with FTD, and 8 (3.3%) 
with MCI.
The pRBD group had male predominance (30 men vs. 17 
women, p = 0.001), was younger (p = 0.025, 95% CI 0.023, 0.029), 
had higher score on UPDRS motor scale (p = 0.004, 95% CI 0.004, 
0.006), was more likely to use anti-parkinsonian medication 
(28.3% vs. 4.7%, p =  0.001), but no other types of medication 
that could influence on CNS or sleep (i.e., benzodiazepines, anti-
depressants, neuroleptics, melatonin). Detailed demographical 
and clinical data for RBD and non-RBD patients at baseline are 
presented in Table 1.
Total number of subject and number of subjects with pRBD 
and percentage among diagnosis analyzed in each follow-up is 
presented in Figure 1.
Longitudinally, there was no statistically significant inter-
action effect between time and RBD vs. non-RBD regarding 
progression rates measured with MMSE or other neuropsycho-
logical tests corrected for age, sex, and education (see Table 2).
Nevertheless, it is worth to note that even though we did not 
find any interaction differences between time and cognition, the 
RBD positive group performed significantly poorer in MMSE 
figure copying, VOSP Cube, TMT A, and Stroop Words in com-
parison to RBD negative as seen in main effect (see Figures 2–5). 
Due to bradykinesia and bradyphrenia, one of the main symp-
toms in PDD and DLB, and possible confounders on tests Stroop 
tests, we controlled it for UPDRS scores. This did not change the 
results, except from TMT A, where performance time no longer 
were statistically different between pRBD-positive and -negative 
subjects.
Because our cohort was heterogeneous within diagnosis, we 
also analyzed the AD group separately to see if there were any 
differences. The DLB group was too small for such statistical 
FigUre 1 | Number of subjects total and REM sleep behavior disorder (RBD) positive in each follow-up (*percentage of RBD positive patients within each 
diagnostic group; sum is not 100%).
TaBle 2 | Effects of probable RBD (pRBD) and interaction between pRBD and time in dementia cohort (shown only statistically significant findings).
prBD interaction prBD*fu
Main effect (F, p) prBD (+), fixed coefficient est (sD), t p 95% ci Main effect (F, p)
MMSE pentagon 8.002, 0.005 −1.83 (0.7), −2.613 0.009 −3.203, −0.454 1.231, 0.297
VOSP Cube 16.94, <0.001 −0.31 (0.13), −2.441 0.015 0.006, 0.556 1.335, 0.256
TMT A 18.44, 0.001 82.2 (29.98), 2.742 0.006 −141.01, −23.32 1.327, 0.259
9.11, 0.003a 57, 38, 31.22, −1.838a 0.067a −118, 74, 3.99a 1.553, 0.187a
Stroop W 16.11, <0.001 −12.42 (5.71), −2.172 0.030 1.186, 23.651 0.26, 0.904
aCorrected for Unified Parkinson’s Disease Rating Scale.
MMSE, Mini Mental State Examination; VOSP, Visual Object and Space Perception; TMTA, Trail Making Test A; Stroop W, Stroop Words.
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analyses. Patients with AD and positive RBD performed poorly 
on MMSE and Stroop Word in comparison with RBD negative 
patients, and had statistically significant more rapid decline in 
VOSP Cube (see Table 3).
DiscUssiOn
The main finding in this study was that there were no differences 
in rate of cognitive decline measured with MMSE in dementia 
FigUre 2 | Estimated means: fu*probable REM sleep behavior disorder 
(RBD). Target: Mini Mental State Examination (MMSE) copy figure. 
Continuous predictors are fixed at the following values: BL_
EDUCATION = 9.7, age = 76.
FigUre 3 | Estimated Means: fu*probable REM sleep behavior disorder 
(RBD). Target: BL: visual object and space perception (VOSP) cube analysis 
(#/10 blocks, without try-out questions). Continuous predictors are fixed at 
the following values: BL_EDUCATION = 9.7, age = 76.
FigUre 4 | Estimated Means: fu*probable REM sleep behavior disorder 
(RBD). Target: BL: Trailmaking test A, seconds. Continuous predictors are 
fixed at the following values: BL_EDUCATION = 9.8, age = 76.
FigUre 5 | Estimated Means: fu*probable REM sleep behavior disorder 
(RBD). Target: BL: Stroop Words. Continuous predictors are fixed at the 
following values: BL_EDUCATION = 9.7, age = 76.
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patients with or without pRBD. Similarly, patients in both groups 
declined equally in all neuropsychological tests measuring short 
and delayed verbal memory, verbal fluency, executive functions, 
and visuospatial abilities during 4 years of observation.
Since many studies have shown that iRBD is a risk factor for 
developing cognitive problems, neurodegenerative disorders and 
can accelerate cognitive dysfunction in PD, one could expect 
a faster progression of cognitive deficits in the RBD-positive 
dementia group. In a very similar, longitudinal study on PD in 
early stages, it is postulated that RBD could reflect more severe 
neurodegeneration and contribute to greater rates of cognitive 
decline (24). However, our data do not support the hypothesis 
that the occurrence of RBD is associated to an accelerated demen-
tia progression.
Lack of differences in progression speed can be explained by 
the hypothesis that subtle differences in more advanced stadiums 
of cognitive impairment disappear as a consequence of reduc-
tion in multiple cognitive domains and overlapping pathology, 
but we did not observe such trend in earlier follow-ups where 
dementia was not very advanced. This suggests that RBD may 
be a part of established, more advanced neurodegeneration, and 
probably not associated with different rate of progression at this 
stage of dementia generally. There are, so far, more evidences for 
that synucleinopathy probably proceeds RBD, than the opposite. 
Previously published studies in iRBD have shown reduction 
in dopamine transporters striatal uptake before appearance 
of other extrapyramidal symptoms (31, 32). Moreover, iRBD 
patients often present other markers of alpha-synucleinopathy 
such as hyperechogenicity of the substantia nigra or hyposmia 
TaBle 3 | Effects of probable RBD (pRBD) and interaction between pRBD and time in AD cohort (n = 122) (shown only statistically significant findings).
prBD interaction prBD*fu
Main effect (F, p) Fixed coefficient est (sD), t p 95% ci Main effect (F, p) Fixed coefficient est 
(sD), t
p 95% ci
MMSE 4.214, 0.041 −0.30 (0.09), −3.27 0.001 0.121, 0.485 1.231, 0.297 – –
VOSP Cube 9.05, 0.003 −0.28 (0.19), −1.47 0.141 – 4.697, 0.001 −3.04 (1.23), −2.471 0.014 −4.087, 
−0.074
Stroop W 16.11, <0.001 −12.42 (5.71), −2.17 0.03 1.186, 23.651 0.26, 0.904 – –
MMSE, Mini Mental State Examination; VOSP, visual object and space perception; TMTA, Trail Making Test A; Stroop W, Stroop Words.
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(33). Furthermore, two autopsy case studies in iRBD patients 
revealed pathology consistent with alpha-synucleinopathy (34, 
35). Therefore, RBD may be considered as a marker of alpha-
synucleinopathy rather than primary risk factor, which influences 
progression rate itself (36). Similar hypothesis is mentioned in a 
study of Manni et al. (12).
Furthermore, RBD is also highly predominant in MSA, with a 
prevalence of 88% in a recent study by Palma (37). Thus, almost 
all MSA patients should develop dementia, but dementia is not 
as common in MSA (15%) as in other synucleinopathies (PDD 
or DLB) (38). This fact supports again the hypothesis that RBD is 
an additional feature or consequence of alpha-synucleinopathy, 
rather than a risk factor for cognitive impairment itself.
On the other hand, RBD could theoretically have negative 
effect on cognition as sleep affecting pathology. REM sleep is 
important for memory consolidation and stabilization (39). 
Reduction in REM sleep leads to impairment in all learning 
phases and memory formation (40). However, several studies 
show that RBD is not necessary related to lack of REM sleep 
(11, 20), so REM sleep deprivation does not seem to be the whole 
explanation for impaired cognition in RBD.
As also shown in previous studies, we found that RBD-positive 
patients had in general lower average scores in tests measuring 
visuospatial abilities and executive functions (MMSE pentagon, 
VOSP Cube, TMT A and Stroop Words), which corresponds 
with neuropsychological profile seen in alpha-synucleinopathies. 
Reduced processing speed in TMT A is probably related to 
presence of more advanced parkinsonian symptoms in the RBD 
group, since after controlling for the UPDRS score, there were no 
longer any significant differences. Poorer performances in pRBD 
in executive functions/attention and visuospatial abilities from 
the beginning indicate earlier and longer duration of pathology, 
because our patients with pRBD have had longer duration of 
dementia symptoms from debut to baseline.
The RBD-positive AD patients had a faster decline on VOSP 
Cube. It was not found in other tests tapping the same function, 
and it could be due to type I error. Therefore, this needs confirma-
tion in future studies before taken as a fact.
limitations and advantages
A major limitation of our study was lack of polysomnography 
validation of RBD. Diagnosis of pRBD was based on bed-partner 
report on MSQ and, therefore, only anamnestic, but sensitivity 
and specificity of MSQ in diagnosing pRBD are estimated to 98 
and 74%, respectively (29). It should be noted that MSQ can both 
underestimate, if informant is not aware of sleep problem, or 
overestimate, if obstructive sleep apnea symptoms mimic RBD. 
In our study group, near 50% of the informants reported that 
their relatives with dementia also had OSA symptoms (snoring or 
breath stops). Boot et al. suggest that MSQ only has 0.66 positive 
predictive value, which means that even more patients could have 
RBD (14). In all dementia types, prevalence of RBD is estimated 
to 18.5% (41). Prevalence of pRBD in our dementia cohort was 
19.1% (studies share partially same group of participants), but 
true prevalence of RBD in dementia is not yet known. We mainly 
found negative results in this study and have not adjusted the alpha 
level, even though we have performed multiple analyses. Positive 
findings could, thus, hypothetically be a result of coincidence.
To the best of our knowledge, this study is the first to shed 
light on the question of how the presence of RBD in dementia 
influences cognitive performance, dementia progression, and 
cognitive changes over time. In addition, it is one of the larg-
est cohorts of RBD patients with longitudinal follow-up. Our 
patients were referred to a memory clinic, not a sleep center, thus 
a selection bias leading to overrepresentation of pRBD is unlikely. 
The current study cohort was assessed regarding RBD inducing 
medication and no such association was found (42). Structural 
imaging (CT or MRI) was also performed in all participants, 
which made it possible to exclude subjects with major structural 
lesions that could secondarily lead to RBD. Not all previous stud-
ies have used such exploration. The statistical method, GLMM, 
has a clear advantage in this kind of longitudinal study with 
multiple follow-up points.
conclusion and Perspectives
Despite several studies having shown cognitive differences 
between “RBD sufferers” and controls without RBD, our findings 
did not indicate that pRBD is a risk factor for faster cognitive 
decline in established dementia. Still, little is known about how 
presence of RBD influences cognition and in what way. Further 
longitudinal studies on larger groups are needed, both in healthy 
subjects and patients who have developed a neurodegenerative 
condition, and with standardized batteries of neuropsychological 
assessment.
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